Menu Back toSession-4-Immunotherapies

Pharmacovigilance and Risk Management Strategies Conference


Session 4: Special Safety Considerations in Benefit-Risk Equipoise of Allogeneic Chimeric Antigen Receptor T (alloCAR-T) Cell Therapies

Session Chair(s)

William  Gregory, PhD

William Gregory, PhD

  • Senior Director, Safety and Risk Management
  • Pfizer Inc, United States
Session 4: Special Safety Considerations in Benefit-Risk Equipoise of Allogeneic Chimeric Antigen Receptor T (alloCAR-T) Cell Therapies

Speaker(s)

Peter F. Bross, MD

Speaker

Peter F. Bross, MD

  • Medical Review Officer OTAT, CBER
  • FDA, United States
William  Gregory, PhD

Speaker

William Gregory, PhD

  • Senior Director, Safety and Risk Management
  • Pfizer Inc, United States